Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment

Journal of Affective Disorders

Volumn 204, Issue , 2016, Pages 40-47

  Weisler, Richard H ^a,b   Ota, Ai ^c   Tsuneyoshi, Kana ^c   Perry, Pamela ^d   Weiller, Emmanuelle ^e   Baker, Ross A ^d   Sheehan, David V ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Richard H Weisler MD and Associates   (United States)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e H LUNDBECK A S   (Denmark)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Brexpiprazole; Functioning; Major depressive disorder; Work; Young adults

Indexed keywords

BREXPIPRAZOLE; ANTIDEPRESSANT AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AKATHISIA; ANXIETY; ARTICLE; DEPRESSION; DEPRESSION ASSESSMENT; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MYOCLONUS; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHOOL; SEDATION; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SOCIAL LIFE; SOMNOLENCE; WEIGHT GAIN; WORK ENVIRONMENT; WORK LIMITATIONS QUESTIONNAIRE; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION; EMPLOYMENT; FOLLOW UP; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; STUDENT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EMPLOYMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; STUDENTS; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84975256656     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.06.001     Document Type: Article

References (56)

1. D.A. Adler, T.J. McLaughlin, W.H. Rogers, H. Chang, L. Lapitsky, and D. Lerner Job performance deficits due to depression Am. J. Psychiatry 163 2006 1569 1576
2. A.C. Altamura, M. Buoli, A. Caldiroli, L. Caron, C. Cumerlato Melter, C. Dobrea, M. Cigliobianco, and F. Zanelli Quarantini Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study J. Affect. Disord. 182 2015 70 75
3. L. Andrade, J.J. Caraveo-Anduaga, P. Berglund, R.V. Bijl, G.R. de, W. Vollebergh, E. Dragomirecka, R. Kohn, M. Keller, R.C. Kessler, N. Kawakami, C. Kilic, D. Offord, T.B. Ustun, and H.U. Wittchen The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys Int. J. Methods Psychiatr. Res. 12 2003 3 21
4. T.R. Barnes A rating scale for drug-induced akathisia Br. J. Psychiatry 154 1989 672 676
5. P. Bech, M. Lunde, and M. Unden Social Adaptation Self-evaluation Scale (SASS): psychometric analysis as outcome measure in the treatment of patients with major depression in the remission phase Int. J. Psychiatry Clin. Pract. 6 2002 141 146
6. R.H. Belmaker, and G. Agam Major depressive disorder N. Engl. J. Med. 358 2008 55 68
7. H.G. Birnbaum, R.C. Kessler, D. Kelley, R. Ben-Hamadi, V.N. Joish, and P.E. Greenberg Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance Depression Anxiety 27 2010 78 89
8. E. Brunner, M. Tohen, O. Osuntokun, J. Landry, and M.E. Thase Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder Neuropsychopharmacology 39 2014 2549 2559
9. Bureau of Labor Statistics. 2015b. Unemployment Rates by Age, Sex, and Marital Status, Seasonally Adjusted. Available at: (http://www.bls.gov/web/empsit/cpseea10.htm). (accessed 01.05.15.).
10. Bureau of Labor Statistics. 2015a. The Employment Situation - March 2015. Available at: (http://www.bls.gov/schedule/archives/empsit-nr.htm#current). (accessed 01.05.15.).
11. D. Chisholm, K. Sweeny, P. Sheehan, B. Rasmussen, F. Smit, P. Cuijpers, and S. Saxena Scaling-up treatment of depression and anxiety: a global return on investment analysis Lancet Psychiatry 3 2016 415 424
12. T.J. Classen, and R.A. Dunn The effect of job loss and unemployment duration on suicide risk in the United States: a new look using mass-layoffs and unemployment duration Health Econ. 21 2012 338 350
13. K.R. Connolly, and M.E. Thase If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies Drugs 71 2011 43 64
14. M. Fava, D.V. Iosifescu, P. Pedrelli, and L. Baer Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire Psychother. Psychosom. 78 2009 91 97
15. D.M. Fergusson, and L.J. Woodward Mental health, educational, and social role outcomes of adolescents with depression Arch. Gen. Psychiatry 59 2002 225 231
16. P.E. Greenberg, A.A. Fournier, T. Sisitsky, C.T. Pike, and R.C. Kessler The economic burden of adults with major depressive disorder in the United States (2005 and 2010) J. Clin. Psychiatry 76 2015 155 162
17. W. Guy ECDEU assessment manual for psychopharmacology (revised) M. Hamilton, Hamilton Anxiety Scale 1976 National Institute of Mental Health Rockville, MD 193 198
18. W. Guy ECDEU Assessment Manual for Psychopharmacology 1976 National Institute of Mental Health Rockville, MD 76 338
19. R. Halpern, A. Nadkarni, I. Kalsekar, H. Nguyen, R. Song, R.A. Baker, and J.C. Nelson Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data Ann. Pharmacother. 47 2013 933 945
20. M. Hamilton A rating scale for depression J. Neurol. Neurosurg. Psychiatry 23 1960 56 62
21. C. Han, S.M. Wang, M. Kato, S.J. Lee, A.A. Patkar, P.S. Masand, and C.U. Pae Second-generation antipsychotics in the treatment of major depressive disorder: current evidence Expert. Rev. Neurother. 13 2013 851 870
22. H.L. Hees, M.W. Koeter, and A.H. Schene Longitudinal relationship between depressive symptoms and work outcomes in clinically treated patients with long-term sickness absence related to major depressive disorder J. Affect. Disord. 148 2013 272 277
23. W.W. Ishak, K. Balayan, C. Bresee, J.M. Greenberg, H. Fakhry, S. Christensen, and M.H. Rapaport A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting Qual. Life Res. 22 2013 585 596
24. U. Jonsson, H. Bohman, A. Hjern, L. von Knorring, G. Olsson, and A.L. von Knorring Subsequent higher education after adolescent depression: a 15-year follow-up register study Eur. Psychiatry 25 2010 396 401
25. R. Kellner A symptom questionnaire J. Clin. Psychiatry 48 1987 268 274
26. R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, K.R. Merikangas, A.J. Rush, E.E. Walters, and P.S. Wang The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) J. Am. Med. Assoc. 289 2003 3095 3105
27. R.C. Kessler The costs of depression Psychiatr. Clin. N. Am. 35 2012 1 14
28. E.A. Khawam, G. Laurencic, and D.A. Malone Jr. Side effects of antidepressants: an overview Clevel. Clin. J. Med. 73 2006 351 361
29. P.M. Krueger, M.K. Tran, R.A. Hummer, and V.W. Chang Mortality attributable to low levels of education in the United States PLoS One 10 2015 e0131809
30. Z.G. Laoutidis, and C. Luckhaus 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis Int. J. Neuropsychopharmacol. 17 2014 823 832
31. D. Lerner, B.C. Amick III, W.H. Rogers, S. Malspeis, K. Bungay, and D. Cynn The Work Limitations Questionnaire Med. Care 39 2001 72 85
32. D. Lerner, D.A. Adler, W.H. Rogers, H. Chang, L. Lapitsky, T. McLaughlin, and J. Reed Work performance of employees with depression: the impact of work stressors Am. J. Health Promot. 24 2010 205 213
33. K. Maeda, H. Sugino, H. Akazawa, N. Amada, J. Shimada, T. Futamura, H. Yamashita, N. Ito, R.D. McQuade, A. Mork, A.L. Pehrson, M. Hentzer, V. Nielsen, C. Bundgaard, J. Arnt, T.B. Stensbøl, and T. Kikuchi Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator J. Pharmacol. Exp. Ther. 350 2014 589 604
34. K. McKeage Adjunctive brexpiprazole: a review in major depressive disorder CNS Drugs 30 2016 91 99
35. M. McQuilken, J. Zahnisera, J. Novack, R. Starska, A. Olmos, and G. Bond The work project survey: consumer perspectives on work J. Vocat. Rehab. 18 2003 59 68
36. S.A. Montgomery, and M. Åsberg A new depression scale designed to be sensitive to change Br. J. Psychiatry 134 1979 382 389
37. Nelson J.C., Skuban A., Zhang P., Weiller E., Weiss C. 2015. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: Results from two 52-week open-label studies abstract (no. 57 plus poster). In: Proceedings of the American Psychiatric Association 168th Annual Meeting, 16-20 May 2015, Toronto, Canada.
38. K. Nieuwenhuijsen, B. Faber, J.H. Verbeek, A. Neumeyer-Gromen, H.L. Hees, A.C. Verhoeven, C.M. van der Feltz-Cornelis, and U. Bultmann Interventions to improve return to work in depressed people Cochrane Database Syst. Rev. 2014 12
39. G.I. Papakostas Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder J. Clin. Psychiatry 70 Suppl 6 2009 S16 S25
40. G.I. Papakostas Major depressive disorder: psychosocial impairment and key considerations in functional improvement Am. J. Manag. Care 15 2009 S316 S321
41. V. Patel, A.J. Flisher, S. Hetrick, and P. McGorry Mental health of young people: a global public-health challenge Lancet 369 2007 1302 1313
42. M. Pompili, M. Innamorati, V.C. Di, S. Baratta, V. Masotti, A. Badaracco, P. Wong, D. Lester, P. Yip, P. Girardi, and M. Amore Unemployment as a risk factor for completed suicide: a psychological autopsy study Arch. Suicide Res. 18 2014 181 192
43. K. Posner, G.K. Brown, B. Stanley, D.A. Brent, K.V. Yershova, M.A. Oquendo, G.W. Currier, G.A. Melvin, L. Greenhill, S. Shen, and J.J. Mann The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults Am. J. Psychiatry 168 2011 1266 1277
44. A.J. Rush, M.H. Trivedi, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, D. Warden, G. Niederehe, M.E. Thase, P.W. Lavori, B.D. Lebowitz, P.J. McGrath, J.F. Rosenbaum, H.A. Sackeim, D.J. Kupfer, J. Luther, and M. Fava Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report Am. J. Psychiatry 163 2006 1905 1917
45. D.V. Sheehan, K. Harnett-Sheehan, and B.A. Raj The measurement of disability Int. Clin. Psychopharmacol. 11 Suppl 3 1996 89 95
46. K.H. Sheehan, and D.V. Sheehan Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale Int. Clin. Psychopharmacol. 23 2008 70 83
47. D.V. Sheehan, J. Locklear, H. Svedsater, and C. Datto Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate Int. Clin. Psychopharmacol. 27 2012 239 248
48. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side effects Acta Psychiatr. Scand. Suppl. 212 1970 11 19
49. M.E. Thase, J.M. Youakim, A. Skuban, M. Hobart, C. Augustine, P. Zhang, R. McQuade, W.H. Carson, M. Nyilas, R. Sanchez, and H. Eriksson Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a Phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants J. Clin. Psychiatry 76 2015 1224 1231
50. M.E. Thase, J.M. Youakim, A. Skuban, M. Hobart, P. Zhang, R. McQuade, M. Nyilas, W.H. Carson, R. Sanchez, and H. Eriksson Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a Phase 3, randomized, double-blind study J. Clin. Psychiatry 76 2015 1232 1240
51. M.H. Trivedi, D.W. Morris, S.R. Wisniewski, I. Lesser, A.A. Nierenberg, E. Daly, B.T. Kurian, B.N. Gaynes, G.K. Balasubramani, and A.J. Rush Increase in work productivity of depressed individuals with improvement in depressive symptom severity Am. J. Psychiatry 170 2013 633 641
52. M. Wang, K. Alexanderson, B. Runeson, and E. Mittendorfer-Rutz Sick-leave measures, socio-demographic factors and health care as risk indicators for suicidal behavior in patients with depressive disorders - a nationwide prospective cohort study in Sweden J. Affect. Disord. 173 2015 201 210
53. D. Warden, A.J. Rush, S.R. Wisniewski, I.M. Lesser, M.E. Thase, G.K. Balasubramani, K. Shores-Wilson, A.A. Nierenberg, and M.H. Trivedi Income and attrition in the treatment of depression: a STAR∗D report Depression Anxiety 26 2009 622 633
54. M.A. Whooley, C.I. Kiefe, M.A. Chesney, J.H. Markovitz, K. Matthews, and S.B. Hulley Depressive symptoms, unemployment, and loss of income: the CARDIA Study Arch. Intern. Med. 162 2002 2614 2620
55. B.M. Wright, E.H. Eiland III, and R. Lorenz Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature Pharmacotherapy 33 2013 344 359
56. A. Yur'yev, A. Varnik, P. Varnik, M. Sisask, and L. Leppik Employment status influences suicide mortality in Europe Int. J. Soc. Psychiatry 58 2012 62 68